Positive Phase II Study Data Suggest ARAKODA® (tafenoquine) Numerically Improved Clinical Recovery in Patients with Mild-Moderate COVID-19 Disease
Our team is committed to creating innovative, potentially lifesaving medicines to significantly impact the quality of life for those affected by infectious diseases worldwide.
Cases and 1 Million deaths in the U.S. from COVID-19 infections
Annual deaths from malaria globally
Travelers to endemic regions per annum
Dengue infections per year